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p=0.01) , FilterWire patients treated with IIb/IIIa, despite their high risk profile, had 30d
MACE rates (9.9%) similar to their counterparts not on IIb/IIIa (9.5%, p=1.0). In fact, IIb/
IIIa in conjunction with FilterWire was associated with a higher rate of successful stent
deployment (100% vs 96.8% p=0.02), and a lower incidence of reduced distal flow or
ischemia during FilterWire use (3.9% vs 9.6% p=0.05).
Conclusions: 1) Profound platelet inhibition using IIb/IIIa antagonists, in conjunction with
distal filter protection devices, may enhance procedural safety and improve late out-
comes for high-risk patients during SVG stenting. 2) Further study is warranted to deter-
mine how IIb/IIIa inhibition may improve filter function, and allow optimization of filter
designs.
9:00 a.m.
830-3 Impact of Vessel Size on Outcomes of Different Distal 
Protection Devices During Saphenous Vein Graft 
Intervention: A FIRE Trial Substudy
Aravind Swaminathan, Howard C. Herrmann, Campbell Rogers, James Hermiller, Robert 
Feldman, Patrick Hall, Robert Haber, A. Masud, Patrick Cambier, Ron P. Caputo, David 
A. Cox, Ramona Pop, Martin Fahy, Roxana Mehran, Gregg W. Stone, Hospital of the 
University of Pennsylvania, Philadelphia, PA, The Cardiovascular Research Foundation, 
New York, NY
Background: In the FIRE trial, distal protection with FilterWire EX (FW) was as effective
as GuardWire (GW) in preventing MACE after SVG PCI. The relation between vessel
size and MACE with distal protection devices is unknown.
Methods: 651 patients were randomized to FW or GW. The trial inclusion criterion (3.5-
5.5 mm) for reference vessel diameter (RVD) was based on visual estimates which were
larger than by QCA (median 4.01 vs. 3.31 mm). For this analysis, patients were grouped
by tertiles of QCA RVD: <3.04 mm (small), 3.04-3.59 mm (medium), and >3.59 mm
(large).
Results: Baseline characteristics were similar, but large vessels were more common in
men (p=0.006), less frequent in diabetics (0.008), and more likely to exhibit plaque ulcer-
ation (p=0.004) and thrombus (p=0.04). At 30 days, MACE (death, MI (CK-MB>3x nl) and
TVR) occurred in 7.0%, 10.1%, 14.8% of pts with small, medium, and large vessels,
respectively (p= 0.04). 90% of MACE consisted of peri-procedural MI. MACE stratified by
device and QCA vessel size appears in the Table.
Conclusions: In this randomized trial of SVG PCI with distal protection, the incidence of
MI and MACE was two-fold higher in large vessels with more complex lesions. MACE
rates with the FW, but not GW, were strongly vessel size dependent. FW had a signifi-
cantly lower MACE rate than GW in small vessels, with no difference in the medium and
large vessels. The mechanism and clinical implications of the differential vessel size
dependence of distal protection devices requires further study.
9:15 a.m.
830-4 Evaluation of a Distal Protection Filter Device in 
Patients With Acute Myocardial Infarction: Final Results 
of the DIPLOMAT Study
Thierry Lefèvre, Philippe Guyon, Bernhard Reimers, Jean-Marie Fauvel, Michel Pansieri, 
Marie-Pierre Dewez, Institut Cardiovasculaire Paris Sud, Massy, France, Centre 
Cardiologique du Nord, Saint Denis, France
Background: Primary angioplasty and stenting is now the gold standard in the treatment
of acute myocardial infarction (AMI). However, despite a high rate of epicardial flow, myo-
cardial tissue reperfusion remains relatively low as assessed by ST segment resolution.
Distal embolization of the thrombotic lesion during PCI could play a major role and this
may be improved by distal protection.
Aim of the study: To evaluate the effectiveness of distal protection with the Angio-
Guard™XP embolic protection device (AG), using a simple and non subjectivean objec-
tive and easily measurable marker of myocardial reperfusion: ST segment resolution.
Methods: A prospective, randomized, multicenter study is conducted in 60 pts with AMI <
12 hours. Pts who meet the eligibility criteria are randomized either to the treatment
group (PCI combined with AG) or to the control group (PCI only). The primary endpoint is
absolute ST segment resolution post-PTCAThe primary endpoint is absolute resolution
of the sum of ST segment 1 hour post PCI and secondary endpoints are ST segment res-
olution >50%, a composite of slow flow, no reflow or distal embolization; regional wall
motion index by echocardiography at discharge and 6-month; TIMI frame count post-PCI
and ability of the AG to retrieve debris and MACE at 1- and 6-month post-procedure.
Results: 56 pts were randomized to date, both groups were comparable (age 61+12 yrs,
diabetes 15%, anterior MI 49%, TIMI flow 0-1 pre PCI 70%). AG was Ssuccessfully
placed in all pts in the treatment armment of the AngioguardTM XP was obtained in all the
25 Pts assigned to the treatment group. Debris were captured in 82% of the filters with a
diameter of 344+306 µm. Absolute ST segment resolution was 15.8+15.3 mm in the
treatment arm vs 9.6+6.7 mm in the control arm (p=0.048). completeST segment resolu-
tion was obtained in 80 vs 73 % (p=NS). At 28 days, death occurred in 0 vs 4.2% (p=NS)
and death or MI in 3.3 vs 8.3% (p=NS), respectively.
Conclusion: These preliminary results show that the AngioGuard™XP devices effectively
and safely captured plaque debris in acute MI. It is associated with improved myocardial
reperfusion as assessed by ST segment resolutionM. Complete six-month data will be
presented at the meeting.
9:30 a.m.
830-5 The Impact of Myocardial Blush Grade on Clinical 
Outcomes of Patients Treated With Saphenous Vein 
Grafts and Thrombotic Native Coronary Arteries: 
Analysis From the X-TRACT Trial
Yoshihiro Tsuchiya, Alexandra J. Lansky, Ricardo A. Costa, Roxana Mehran, Manuela 
Negoita, Ecaterina Cristea, Horia Marginean, Maria Corral, Moses Tarawali, Joseph 
Babb, David A. Cox, Gregg W. Stone, Cardiovascular Research Foundation, New York, 
NY
Myocardial perfusion (MBG) is a predictor of infarct size, and short- and long-term sur-
vival in the setting of acute MI.Whether MBG predicts outcomes following elective PCI in
high risk patients with SVG disease or thrombotic native coronary lesions is unknown.
Methods and Results: In the randomized X-TRACT trial, 797 patients underwent PCI to
treat diseased SVGs (72.4%) and thrombotic native coronary arteries (27.2%). MBG was
analyzed after final intervention and was classified into 3 groups: absent (MBG 0/1)
reduced (MBG 2) and normal (MBG 3) perfusion. The final MBG frequency was 69%
MBG 3, 21% MBG 2, 10% MBG 0/1, and among the 94% of patients with final TIMI 3 flow
MBG 3was achieved in 71% and MBG 0/1 in 8%. Clinical outcomes are shown in the
Table.
*P<0.05 vs. MBG 0 /1
There was no significant difference in the outcomes between patients in the MBG 2 and
MBG 3 groups.
Conclusions: In patients undergoing elective PCI in high risk lesions, normal myocardial
perfusion is achieved in only 71% despite normal epicardial flow. Absent myocardial per-
fusion is an important prognostic marker of 6 month complications even among patients
who achieve normal epicardial flow (TIMI 3).
9:45 a.m.
830-6 Relationship Between Embolic Material Retrieval and 
Adverse Events With Different Distal Protection Devices 
During Saphenous Vein Graft Stenting
Giora Weisz, Campbell Rogers, James Hermiller, Robert Feldman, Patrick Hall, Robert 
Haber, Zaki Masud, Patrick Cambier, Ronald P. Caputo, Mark Turco, Richard Kovach, 
Bruce Brodie, Howard C. Herrmann, David A. Cox, Roxana Mehran, Gregg W. Stone, 
Cardiovascular Research Foundation, New York, NY
Background: The high rate of peri-procedural MI in saphenous vein grafts (SVG) stent-
ing is reduced with distal protection devices. Whether retrieval of embolic material (EM) is
predictive of adverse events has not been studied.
Methods: In FIRE trial, 651 pts undergoing SVG stenting were randomized to distal pro-
tection with FilterWire EX vs. GuardWire balloon occlusion and aspiration system. Based
on operators’ visual assessment, information whether EM was captured was docu-
mented in 610 pts.
Results: EM was captured in 443 pts (73%); 233 (76%) of the FilterWire pts, and 210
(69%) of the GuardWire pts (p=0.12). Demographics, clinical presentation, and lesion
characteristics were similar in pts with or without EM captured. Selected procedure char-
acteristics and in-hospital outcomes appear in table. Multivariate analysis revealed that
reference vessel diameter and procedure duration, but not capture of embolic material,
were independent predictors of MI.
Conclusions: Following SVG stenting, visually evident retrieval of embolic material with
the GuardWire, but not with the FilterWire, is associated with a higher rate of peri-proce-
dural MI. Further study is warranted to determine whether this observation reflects
incomplete aspiration of embolized material with the GuardWire system, or sub-optimal
capture of embolic debris with the FilterWire.
Diameter Range 
(QCA)
FilterWire GuardWire Relative Risk 
[95% CI]
P value
<3.04 mm 3.0% (3/100) 10.9% (11/101) 0.28 (0.08-0.96) 0.05
3.04-3.59 mm 9.1% (10/110) 11.4% (10/88) 0.80 (0.35-1.84) 0.64
>3.59 mm 16.7% (17/102) 12.9% (13/101) 1.29 (0.66-2.52) 0.55
p=0.003 p=0.85
6 Month Results MBG 0/1
N=73
MBG 2
N=149
MBG 3
N=491
Overall P-value
Non-QMI, % 35.6 12.5* 15.0 * <0.0001
Q-MI, % 4.1 1.4 0.8 * 0.07
Death, % 4.1 2.8 1.9 0.44
Death or Any MI % 42.5 15.3* 17.3* <0.0001
MACE, % 45.2 20.1* 21.6 * <0.0001
Patients w/ Final TIMI 3 N=53 N=143 N=473
Death, % 3.8 2.9 1.5 0.37
Death or Any MI,% 28.3 13.7* 16.6* 0.05
MACE,% 32.1 18.7* 21.2 0.04
